Previous 10 | Next 10 |
An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an effect that was accompanied by an improvement in neuronal proteins and EEG changes associated with cor...
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 16, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a...
2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...
2023-09-14 13:02:36 ET More on Alzheimer's drug developers Cassava Sciences: Insiders Purchasing Stock, Is The Market Still Buying Simufilam? Prothena: Dunn Appointment And Bristol Opt-In Boost Validation Anavex Life Sciences: Multiple CNS Shots On Goal Awaiting Conv...
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight disease, announced today that RJ Tesi, MD, Chief Executive Officer, and David Moss, Chief Fin...
The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro ™ in patients with early Alzheimer’s disease to the U.K. Boca Raton, Florida, Sept. 05, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. ...
2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...
2023-08-07 17:52:05 ET INmune Bio, Inc. (INMB) Q2 2023 Earnings Conference Call August 07, 2023 04:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer & Chief Medical Officer Conference Call Participants ...
2023-08-07 16:41:20 ET INmune Bio press release ( NASDAQ: INMB ): Q2 GAAP EPS of -$0.36 beats by $0.04 . As of June 30, 2023, the Company had cash and cash equivalents of approximately $47.8 million. For further details see: INmune Bio GAAP EPS of -$0.36 beat...
BOCA RATON, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial...
News, Short Squeeze, Breakout and More Instantly...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...